NYKODE THERAPEUTICS ASA revenue breakdown overview

NYKODE THERAPEUTICS ASA revenue for the last year amounted to 11.78 M EUR, the most of which — 12.13 M EUR — came from its highest performing source at the moment, Novel Vaccines and Immunotherapies, the year earlier bringing 6.57 M EUR. The greatest contribution to the revenue figure was made by United States — last year it brought NYKODE THERAPEUTICS ASA 12.13 M EUR, and the year before that — 6.57 M EUR.